Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
36.36
+0.08 (0.22%)
At close: Jul 24, 2026, 4:00 PM EDT
37.36
+1.00 (2.75%)
After-hours: Jul 24, 2026, 7:34 PM EDT
Agios Pharmaceuticals Revenue
Agios Pharmaceuticals had revenue of $20.75M in the quarter ending March 31, 2026, with 137.75% growth. This brings the company's revenue in the last twelve months to $66.05M, up 78.34% year-over-year. In the year 2025, Agios Pharmaceuticals had annual revenue of $54.03M with 48.03% growth.
Revenue (ttm)
$66.05M
Revenue Growth
+78.34%
P/S Ratio
32.74
Revenue / Employee
$122,311
Employees
540
Market Cap
2.16B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 54.03M | 17.53M | 48.03% |
| Dec 31, 2024 | 36.50M | 9.68M | 36.07% |
| Dec 31, 2023 | 26.82M | 12.58M | 88.36% |
| Dec 31, 2022 | 14.24M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 94.39M | 51.38M | 119.45% |
| Dec 31, 2017 | 43.01M | -26.88M | -38.46% |
| Dec 31, 2016 | 69.89M | 10.77M | 18.22% |
| Dec 31, 2015 | 59.12M | -6.24M | -9.55% |
| Dec 31, 2014 | 65.36M | 39.81M | 155.82% |
| Dec 31, 2013 | 25.55M | 442.00K | 1.76% |
| Dec 31, 2012 | 25.11M | 3.27M | 14.97% |
| Dec 31, 2011 | 21.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 899.11M |
| Zai Lab | 453.28M |
| UroGen Pharma | 140.49M |
| Viridian Therapeutics | 70.92M |
| Mesoblast | 65.38M |
AGIO News
- 4 days ago - Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright - TheFly
- 5 days ago - Agios Pharmaceuticals down 13% at $34.75 on topline results from tebapivat trial - TheFly
- 5 days ago - Agios Pharmaceuticals announces topline results from tebapivat trial - TheFly
- 5 days ago - Agios Pharma to discontinue sickle cell disease treatment development - Reuters
- 5 days ago - Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease - GlobeNewsWire
- 18 days ago - Agios Pharmaceuticals rises 13.5% - TheFly
- 18 days ago - Leerink sees Priority Review designation as positive sign for Agios’ mitapivat - TheFly
- 18 days ago - H.C. Wainwright sees FDA Priority Review as positive signal for Agios’ mitapivat - TheFly